Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arie Regev

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Alimentary Pharmacology & Therapeutics|September 20, 2024
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patientsAnna Fettiplace, John Marcinak, Michael Merz, et al.
Transplantation|April 30, 2003
Preliminary experience with campath 1H (C1H) in intestinal and liver transplantationAndreas G Tzakis, Tomoaki Kato, Seigo Nishida, et al.
The Journal of Applied Laboratory Medicine|December 19, 2022
Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver ChemistryEnaksha Wickremsinhe, Antoniu Fantana, Erwin Berthier, et al.
Transplantation|June 7, 2003
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantationAndreas G Tzakis, Tomoaki Kato, Seigo Nishida, et al.
Drug Safety|December 4, 2025
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert ConsensusAnna Fettiplace, Arie Regev, Alexandre Kiazand, et al.
Alimentary Pharmacology & Therapeutics|February 15, 2019
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitisArie Regev, Melissa Palmer, Mark I Avigan, et al.
Drug Safety|February 14, 2024
Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory TherapyEric B Cohen, Arie Regev, Anju Garg, et al.
Gastroenterology & Hepatology|October 1, 2011
Prospective Evaluation of FIBROSpect II for Fibrosis Detection in Hepatitis C and B Patients Undergoing Laparoscopic BiopsyLennox J Jeffers, Rafael A Cortes, Pablo A Bejarano, et al.
Drug Safety|February 17, 2024
Correction to: Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI InitiativeEric B Cohen, Meenal Patwardhan, Ritu Raheja, et al.
Drug Safety|January 13, 2024
Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI InitiativeEric B Cohen, Meenal Patwardhan, Ritu Raheja, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Alimentary Pharmacology & Therapeutics|September 20, 2024
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patientsAnna Fettiplace, John Marcinak, Michael Merz, et al.
Transplantation|April 30, 2003
Preliminary experience with campath 1H (C1H) in intestinal and liver transplantationAndreas G Tzakis, Tomoaki Kato, Seigo Nishida, et al.
The Journal of Applied Laboratory Medicine|December 19, 2022
Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver ChemistryEnaksha Wickremsinhe, Antoniu Fantana, Erwin Berthier, et al.
Transplantation|June 7, 2003
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantationAndreas G Tzakis, Tomoaki Kato, Seigo Nishida, et al.
Drug Safety|December 4, 2025
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert ConsensusAnna Fettiplace, Arie Regev, Alexandre Kiazand, et al.
Alimentary Pharmacology & Therapeutics|February 15, 2019
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitisArie Regev, Melissa Palmer, Mark I Avigan, et al.
Drug Safety|February 14, 2024
Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory TherapyEric B Cohen, Arie Regev, Anju Garg, et al.
Gastroenterology & Hepatology|October 1, 2011
Prospective Evaluation of FIBROSpect II for Fibrosis Detection in Hepatitis C and B Patients Undergoing Laparoscopic BiopsyLennox J Jeffers, Rafael A Cortes, Pablo A Bejarano, et al.
Drug Safety|February 17, 2024
Correction to: Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI InitiativeEric B Cohen, Meenal Patwardhan, Ritu Raheja, et al.
Drug Safety|January 13, 2024
Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI InitiativeEric B Cohen, Meenal Patwardhan, Ritu Raheja, et al.
Pageof 7